Detail akcie Opko Health online

Business Summary: OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, OPKO Health Inc revenues decreased 13% to $458.4M. Net loss increased from $67.3M to $194.4M. Revenues reflect Pharmaceutical segment decrease from $105.2M to $0K, Diagnostics segment decrease of 21% to $299.2M, United States segment decrease of 17% to $342M, Chile segment decrease of 9% to $44.9M, Ireland segment decrease of 4% to $29.3M.